ONCS - ONCS STOCK NEWS

OncoSec Medical (NASDAQ:ONCS) has published a significant case study on the efficacy of its immunotherapy TAVO (tavokinogene telseplasmid) in combination with KEYTRUDA in a patient with checkpoint-resistant metastatic melanoma. The study, published in the International Journal of Surgery Case Reports, reported complete resolution of treated lesions and an overall body response. This innovative approach offers hope for patients with limited therapeutic options. CEO Daniel O'Connor emphasized the potential of TAVO to activate the immune system in cancer patients unresponsive to existing treatments.

OncoSec Medical (NASDAQ: ONCS) announced an exclusive licensing agreement for the Cliniporator® gene electrotransfer platform from IGEA Clinical Biophysics. This technology will be used in OncoSec's visceral lesion applicator program and has been cleared by the FDA for a Phase 1 trial of CORVax12, its COVID-19 vaccine candidate. The Cliniporator is already in use in over 200 oncology centers internationally, targeting metastatic cancer. The company aims to enhance immune responses against COVID-19 and improve treatments for advanced cancer patients, driven by this innovative technology.

On Nov. 18, 2020, OncoSec Medical (NASDAQ: ONCS) presented key insights from its Analyst & Investor Day, highlighting positive interim data from the KEYNOTE-695 Phase 2b trial of TAVO™ combined with KEYTRUDA® for patients with anti-PD-1 resistant metastatic melanoma. The trial has fully enrolled 100 patients, with a promising 30% overall response rate. Early indications show TAVO's favorable safety profile and potential for immune response enhancement. OncoSec also introduced its CORVax12 vaccine targeting SARS-CoV-2, expected to begin clinical trials soon.

OncoSec Medical (NASDAQ:ONCS) announced promising interim results from its Phase 2b KEYNOTE-695 trial, evaluating TAVO™ plus KEYTRUDA® in metastatic melanoma patients resistant to anti-PD1 therapy. The overall response rate (ORR) reached 30% in the first 54 patients, surpassing the study's 20% efficacy endpoint. Notably, the treatment exhibited a favorable safety profile, with only 5.4% of patients experiencing Grade 3 adverse events. Additionally, OncoSec is advancing its CORVax12 vaccine for SARS-CoV-2, receiving FDA clearance for a Phase 1 trial. The results signal significant potential for both melanoma treatment and COVID-19 vaccination efforts.

OncoSec Medical (NASDAQ:ONCS) announced an Investor and Analyst webinar set for November 11, 2020, showcasing interim data from the KEYNOTE-695 Phase 2b trial evaluating TAVO™ (tavokinogene telseplasmid) combined with KEYTRUDA® for treating anti-PD-1 refractory metastatic melanoma. The webinar will also cover updates on the KEYNOTE-890 trial for metastatic triple negative breast cancer and the CORVax12 COVID-19 vaccine which is entering Phase 1 trials. The session will feature experts discussing clinical data and future directions in immunotherapy.

OncoSec Medical (NASDAQ:ONCS) announced positive interim data from its KEYNOTE-695 Phase 2b clinical trial of TAVO™ (tavokinogene telseplasmid) in combination with KEYTRUDA® (pembrolizumab) for refractory metastatic melanoma. This data will be presented at the SITC 35th Annual Meeting from November 9-14, 2020, including an oral presentation on November 10. The company will also showcase posters on immunological data in metastatic triple negative breast cancer and its COVID-19 vaccine candidate CORVax12. TAVO has received FDA Breakthrough Therapy Designation for metastatic melanoma.

OncoSec Medical has received FDA approval for its Investigational New Drug (IND) application, initiating a Phase 1 trial for CORVax12, a DNA vaccine against SARS-CoV-2. This trial, conducted with Providence Cancer Institute, aims to evaluate the vaccine's safety and immunogenicity in 36 healthy volunteers. CORVax12 combines OncoSec's IL-12 platform with a stabilized SARS-CoV-2 spike glycoprotein, potentially enhancing immune responses compared to existing vaccines. The study will explore if IL-12 can improve antiviral responses, particularly in vulnerable populations.

OncoSec Medical Incorporated (NASDAQ:ONCS) announced the appointment of Sandra Aung, Ph.D., as Senior Vice President and Chief Clinical Development Officer. Dr. Aung will oversee the KEYNOTE-695 Phase 2b trial evaluating the efficacy of TAVO™ in unresectable advanced melanoma, in combination with KEYTRUDA. Dr. Aung has over 20 years of experience in immuno-oncology and played a key role in the development of Nektar Therapeutics' lead clinical compound. She is expected to report new clinical data from KEYNOTE-695 in November. In relation to her role, Dr. Aung received 300,000 stock options.

OncoSec Medical announced the issuance of U.S. Patent No. 10,792,375 on October 6, 2020, enhancing its intellectual property related to its interleukin-12 (IL-12) immunotherapy platform, including the lead candidate TAVO™. This patent is significant as it covers intratumoral electroporation for treating various cancers using immune-stimulatory interleukins. The new patent strengthens OncoSec's competitive position in oncology and expands its existing patent portfolio, which aims to facilitate the development of novel immunotherapy solutions.